Patents by Inventor Kentaro YASHIRO

Kentaro YASHIRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210347773
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 11, 2021
    Applicants: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W. LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
  • Patent number: 11046683
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 29, 2021
    Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W Lindsley, Joshua M. Wieting, Kevin M. McGowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
  • Patent number: 10676438
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: June 9, 2020
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20200157050
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
  • Patent number: 10570093
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Patent number: 10519105
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 31, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
  • Publication number: 20190322662
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 24, 2019
    Applicants: ONO PHARMACEUTICAL CO., LTD., Vanderbilt University
    Inventors: Craig W LINDSLEY, Joshua M. WIETING, Kevin M. MCGOWAN, Jerod S. DENTON, Kentaro YASHIRO, Haruto KURATA, Yoko SEKIOKA, Takahiro MORI, Yuzo IWAKI
  • Publication number: 20190135755
    Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20190127320
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
  • Patent number: 10196358
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 5, 2019
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20180346422
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20170334855
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 8, 2017
    Publication date: November 23, 2017
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Patent number: 9809544
    Abstract: The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 7, 2017
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20170217888
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: October 23, 2015
    Publication date: August 3, 2017
    Applicant: Ono Pharmaceutical Co., Ltd
    Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO